{"id":"W4405273291","doi":"10.1182/bloodadvances.2024014903","title":"Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovation Cluster (Canada)","funders":"Cilag; Berlin Institute of Health; Swedish Orphan Biovitrum; Incyte; BeiGene; Agios Pharmaceuticals; Regeneron Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Gilead Sciences; Sanofi; Pfizer; Les Laboratories Pierre Fabre; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Bendamustine; Refractory (planetary science); Cytokine release syndrome; Rituximab; Oncology; Salvage therapy; Gastroenterology; Lymphoma; Surgery; Chemotherapy; Immunotherapy; Cancer; Chimeric antigen receptor; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005531039,0.0001317995,0.0003139801,0.0002949088,0.00004321708,0.00001544859,0.00007927528,0.00004214005,0.0001428736],"category_scores_gemma":[0.0001477269,0.0001126264,0.00007305788,0.0003927339,0.00006088756,0.0001308632,0.00005016015,0.0001203635,0.000004170131],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007218993,"about_ca_system_score_gemma":0.0001515195,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005524485,"about_ca_topic_score_gemma":0.0004335397,"domain_scores_codex":[0.9986608,0.00005812483,0.0003426971,0.0003488598,0.0003408326,0.0002487063],"domain_scores_gemma":[0.99869,0.000907518,0.00005111333,0.0001916919,0.00008540745,0.00007425142],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01435709,0.04369817,0.3090731,0.003657252,0.0007724647,0.0005556095,0.007568967,0.0000364016,0.07643929,0.003779987,0.0003704175,0.5396913],"study_design_scores_gemma":[0.1140877,0.004866585,0.5501772,0.0007729915,0.0003500687,0.00003395198,0.00226775,0.00158595,0.01575717,0.000400977,0.3092527,0.0004469296],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844513,0.008391415,0.00003745989,0.0001950402,0.0001241729,0.001432917,0.00006871472,0.00005072142,0.005248277],"genre_scores_gemma":[0.9889493,0.001203775,0.0007884449,0.00002586914,0.0001297444,0.00007451411,0.00002929622,0.00003124943,0.008767808],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5392444,"threshold_uncertainty_score":0.459277,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01682718553447772,"score_gpt":0.3415337235392444,"score_spread":0.3247065380047667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}